At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 202 enrolled
Drug / intervention
IPP-201101 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
In Brief
A Phase 3 clinical trial evaluating IPP-201101, Placebo, and 1 other intervention for Lupus Erythematosus, Systemic. Completed, enrolled 202 participants across 30 sites in 8 countries.
Detailed Summary
This current Phase 3 study will evaluate the efficacy and safety of administration of subcutaneous (sc) IPP-201101 in patients with active SLE.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Erythematosus, Systemic
CountriesCzechia, France, Germany, Hungary, Mauritius, Poland, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedJul 2015
Primary CompletionJan 2018
TodayJul 2026
First PostedJul 22, 2015
Enrollment StartMar 1, 2015
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.9 years ago
Interventions
IPP-201101drug
Placebodrug
Standard of Careother